Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 BPM31510 (ubidecarenone) plus gemcitabine in advanced pancreatic cancer
2017-001470-42Phase 2Completed
- Sponsor
- BPGbio
- Start
- Jul 2017
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ubidecarenone nanodispersion in pancreatic cancer (PC), sponsored by BPGbio. Primary endpoint: Overall Response Rate. Started Jul 2017; status: completed.
02
Drugs
ubidecarenone nanodispersion
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on 2017-001470-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001470-42.